Seroquel XR® is the commercial brand name of Quetiapine Fumarate Sustained-release Tablets, an atypical antipsychotic developed by AstraZeneca. It binds to multiple neurotransmitter receptors in the brain to regulate neural activity and relieve psychiatric symptoms. Main IndicationsTreatment of schizophrenia; treatment…
Latuda® is the commercial brand name of Lurasidone Hydrochloride Tablets, an atypical antipsychotic agent developed by Sunovion Pharmaceuticals. It exerts therapeutic effects through balanced antagonism and partial agonism on multiple central nervous system receptors to improve psychotic symptoms. Main IndicationsTreatment…
Fycompa® is the commercial brand name of Perampanel Tablets, a non-competitive AMPA glutamate receptor antagonist developed by Eisai. It reduces excessive neuronal excitation in the brain to exert anti-epileptic effects. Main IndicationsAdjunctive treatment of partial-onset seizures with or without secondary…
Vigabatrin Powder for Oral Solution is commercially sold under the brand name Weigeding®. It is an irreversible inhibitor of GABA transaminase, which elevates brain GABA levels and exerts anti-seizure effects. Main IndicationsAdjunctive treatment of refractory partial-onset seizures with or without…
Hyruan ONE® is the official global commercial brand name, and Yinikang is its Chinese brand name developed by LG Chem. It is a BDDE‑cross‑linked sodium hyaluronate preparation. By injecting into knee joint cavity, it supplements intra‑articular hyaluronic acid, improves joint…
Xgeva® is the official global commercial brand name, and Anjiawei is its Chinese brand name developed by Amgen. It is a fully‑human monoclonal antibody against RANKL. It binds to RANKL specifically, inhibits osteoclast formation, activation and survival, thereby reducing bone…
Tecfidera® is the official global commercial brand name developed by Biogen. It is an oral fumarate derivative. It activates the Nrf2 antioxidant signalling pathway, exerts anti‑oxidative and anti‑inflammatory effects, and modulates immune cell function to reduce autoimmune‑mediated central nervous system…
Fabhalta® is the official global commercial brand name, and Feiheda is its Chinese brand name developed by Novartis. It is an oral proximal complement factor B inhibitor. It targets complement factor B of the alternative complement pathway, blocks abnormal complement‑mediated…
Ocrevus® is the official global commercial brand name, and Luokeshi is its Chinese brand name developed by Roche. It is a humanized anti‑CD20 monoclonal antibody. It selectively depletes CD20‑positive B‑lymphocytes, inhibits pathological autoimmune inflammatory responses in the central nervous system,…
Stelara® is the official global commercial brand name, and Xidanuo is its Chinese brand name developed by Janssen. It is a fully‑human monoclonal antibody. It targets the p40 subunit of interleukin‑12 (IL‑12) and interleukin‑23 (IL‑23), blocks abnormal inflammatory signalling pathways,…